ArticleInnovation (Cambridge (Mass.))2025
β-alkoxy enones for biocompatible primary amine conjugation.
Article in Innovation (Cambridge (Mass.)), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we present an innovative and efficient approach to amine conjugation that offers many advantages over existing methods. Our method employs an easily prepared β-alkoxy enone as the core reagent, achieving unparalleled specificity to primary amines. It operates effectively under neutral pH conditions and at room temperature. This eliminates the need for metal catalysts or additives, thereby simplifying the process and reducing potential contaminants. A key attribute of our method is its remarkable cleanliness, with ethanol as the sole by-product, ensuring minimal environmental and biological impact. The conjugation products exhibit exceptional stability, even in the presence of diverse biomolecules, making this method highly suitable for intricate biological systems. Our approach demonstrates a broad substrate scope, effectively conjugating a range of compounds from lysine derivatives to complex protein and drug conjugates as well as amino-sugar conjugates. Its ability to selectively target different amine types while remaining unreactive toward anilines and secondary amines such as proline underscores its potential for advancing drug development and biologic synthesis. This method marks a significant breakthrough, offering promising avenues for exploration in biochemical and pharmaceutical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.